fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Glatiramer acetate

All strengths: Limited Use, Reason for Use code 535, 536, 537 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 535, 536, 537 required
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]

Copaxone · DIN 02245619 · 20 mg/mL · injection solution pre-filled syringe-1mL Pk

Limited Use, Reason for Use code 535, 536, 537 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 535 or 536 or 537 (criteria below)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 535, 536, 537
Reason for Use code 535 As monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) meeting ALL the following criteria: -Recent neurological examination consistent with the diagnosis of RRMS; AND -Lesions typical of multiple sclerosis on brain magnetic resonance imaging (MRI); AND -Experienced at least 2 clinical attacks in their lifetime with one attack occurring within the prior year; AND -EDSS score less than or equal to 6.0 prior to start of treatment; AND -Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis. Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 536 As monotherapy for the treatment of patients who have experienced a single demyelinating event/ Clinically Isolated Syndrome (CIS) meeting ALL the following criteria: - CIS occurred within the prior 12 months; AND - Recent neurological examination; AND - Lesions typical of CIS confirmed on brain magnetic resonance imaging (MRI); AND - EDSS score less than or equal to 6.0 prior to start of treatment; AND - Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 537 Renewal of therapy for patients diagnosed with relapsing remitting multiple sclerosis (RRMS) or a single demyelinating event /Clinically Isolated Syndrome (CIS) who meet ALL the following criteria: - Used as monotherapy for the treatment of RRMS or CIS; AND - EDSS score less than or equal to 6.0; AND - Disease activity is stabilized as determined by a neurological exam and the number of clinical relapses experienced while on treatment; AND - Prescribed by a neurologist experienced in the treatment of Multiple Sclerosis (MS) OR a prescriber in consultation with a neurologist overseeing the patient's MS. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Glatiramer acetate – See Formulary listing for Glatect Brand(s): Copaxone, Glatect (available as Limited Use drug on ODB formulary) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection Refer to the Executive Officer Communications on the Ministry website for the Ministry’s Biosimilar Policy including frequently asked questions and updates for the biosimilar policy updates. http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx Effective March 31, 2023, the ODB program will start transitioning coverage for Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan® to their biosimilar versions. Effective December 29, 2023, coverage for these originator biologic drugs through the ODB program will not be available for patients and the ODB program will only provide coverage for the biosimilar version of these drugs for all ODB program recipients, with limited exemptions. In general, for ODB program recipients who are already on these biologic drugs, there is up to a 9-month transition period (see the biosimilar switch policy described on page 6 to 8 of this document). It should be noted that after the date when a biosimilar becomes publicly funded for an approved indication, patients initiated on an originator biologic for this same provincially funded indication through support from a manufacturer’s patient support program, will be expected to be provided ongoing access of the originator biologic through the patient’s original payer mechanism (e.g. manufacturer’s patient support program) or to switch to an ODB funded biosimilar version upon meeting specified criteria. The Ministry will no longer consider funding of originator biologics that are part of the biosimilar policy with limited exemptions on or after December 29, 2023. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 226, record 133, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Glatiramer acetate (Coverage is provided for Glatect) Brand(s): Glatect; Copaxone will only be funded for patients who meet a medical exemption as of December 29, 2023 (Refer to the Biosimilar policy) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection Interferon beta-1a Brand(s): Avonex PS, Avonex Pen DOSAGE FORM/ STRENGTH: 30 mcg/0.5mL prefilled syringe for intramuscular injection, 30 mcg single-use prefilled autoinjector Brand(s): Rebif DOSAGE FORM/ STRENGTH: 22 mcg and 44 mcg prefilled syringe for subcutaneous injection, 66 mcg/ml and 132 mcg/ml pre-filled cartridge Interferon beta-1b Brand(s): Betaseron DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection Brand(s): Extavia DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection For the treatment of Clinically Isolated Syndrome (CIS): requests for patients who have experienced a single demyelinating event will be reviewed by external medical experts when the following information is provided: • Date and details of the most recent neurological examination which must have been conducted within the last ninety days of the request; • The patient’s EDSS is less than or equal to 6.0 (please provide EDSS score); AND • The patient’s clinically isolated syndrome occurred within the last twelve months. Duration of Approval: 1 year Renewal requests will be assessed according to the following criteria: • the requesting physician provides the date and details of the patient’s most recent neurological examination and EDSS scores; • the patient’s neurological examination occurred within that last ninety days; • the patient is stable (i.e. no relapses or attacks during the last year) and • the patient’s EDSS is less than or equal to 6.0 242 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 242, record 143, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
1 brand, same coverage
Copaxone · DIN 02245619 Manufacturer: Teva Canada Innovation.; listing date 2024-05-31 Health Canada: Marketed since 2016-01-28 · brand COPAXONE · ATC L03AX13 GLATIRAMER ACETATE · form Solution · route Subcutaneous · ingredients GLATIRAMER ACETATE 20 MG/ML · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245619)

Source record
DIN 02245619: Copaxone Raw flags: sec12=Y, sec3=Y Item: 920000422; group id 918; item number 2192; lccId 00309; manufacturer id TEI Source form: Inj Sol Pref Syr-1mL Pk; strength: 20mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.6522; ministry $27.8587 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245619 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69719
Interchangeable products
Glatiramer Acetate Injection · DIN 02541440 · $27.8587
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245619
Shortage record checked October 6, 2026

Glatiramer Acetate Injection · DIN 02541440 · 20 mg/mL · injection solution pre-filled syringe-1mL Pk

Limited Use, Reason for Use code 535, 536, 537 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 535 or 536 or 537 (criteria below)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 535, 536, 537
Reason for Use code 535 As monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) meeting ALL the following criteria: -Recent neurological examination consistent with the diagnosis of RRMS; AND -Lesions typical of multiple sclerosis on brain magnetic resonance imaging (MRI); AND -Experienced at least 2 clinical attacks in their lifetime with one attack occurring within the prior year; AND -EDSS score less than or equal to 6.0 prior to start of treatment; AND -Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis. Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 536 As monotherapy for the treatment of patients who have experienced a single demyelinating event/ Clinically Isolated Syndrome (CIS) meeting ALL the following criteria: - CIS occurred within the prior 12 months; AND - Recent neurological examination; AND - Lesions typical of CIS confirmed on brain magnetic resonance imaging (MRI); AND - EDSS score less than or equal to 6.0 prior to start of treatment; AND - Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 537 Renewal of therapy for patients diagnosed with relapsing remitting multiple sclerosis (RRMS) or a single demyelinating event /Clinically Isolated Syndrome (CIS) who meet ALL the following criteria: - Used as monotherapy for the treatment of RRMS or CIS; AND - EDSS score less than or equal to 6.0; AND - Disease activity is stabilized as determined by a neurological exam and the number of clinical relapses experienced while on treatment; AND - Prescribed by a neurologist experienced in the treatment of Multiple Sclerosis (MS) OR a prescriber in consultation with a neurologist overseeing the patient's MS. Coverage limit: LU Authorization Period: 1 year Exceptional Access criteria on record are for Brand(s): Copaxone, Glatect (available as Limited Use drug on ODB formulary); DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Glatiramer acetate – See Formulary listing for Glatect Brand(s): Copaxone, Glatect (available as Limited Use drug on ODB formulary) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection Refer to the Executive Officer Communications on the Ministry website for the Ministry’s Biosimilar Policy including frequently asked questions and updates for the biosimilar policy updates. http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx Effective March 31, 2023, the ODB program will start transitioning coverage for Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan® to their biosimilar versions. Effective December 29, 2023, coverage for these originator biologic drugs through the ODB program will not be available for patients and the ODB program will only provide coverage for the biosimilar version of these drugs for all ODB program recipients, with limited exemptions. In general, for ODB program recipients who are already on these biologic drugs, there is up to a 9-month transition period (see the biosimilar switch policy described on page 6 to 8 of this document). It should be noted that after the date when a biosimilar becomes publicly funded for an approved indication, patients initiated on an originator biologic for this same provincially funded indication through support from a manufacturer’s patient support program, will be expected to be provided ongoing access of the originator biologic through the patient’s original payer mechanism (e.g. manufacturer’s patient support program) or to switch to an ODB funded biosimilar version upon meeting specified criteria. The Ministry will no longer consider funding of originator biologics that are part of the biosimilar policy with limited exemptions on or after December 29, 2023. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 226, record 133, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Glatect; Copaxone will only be funded for patients who meet a medical; DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Glatiramer acetate (Coverage is provided for Glatect) Brand(s): Glatect; Copaxone will only be funded for patients who meet a medical exemption as of December 29, 2023 (Refer to the Biosimilar policy) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection Interferon beta-1a Brand(s): Avonex PS, Avonex Pen DOSAGE FORM/ STRENGTH: 30 mcg/0.5mL prefilled syringe for intramuscular injection, 30 mcg single-use prefilled autoinjector Brand(s): Rebif DOSAGE FORM/ STRENGTH: 22 mcg and 44 mcg prefilled syringe for subcutaneous injection, 66 mcg/ml and 132 mcg/ml pre-filled cartridge Interferon beta-1b Brand(s): Betaseron DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection Brand(s): Extavia DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection For the treatment of Clinically Isolated Syndrome (CIS): requests for patients who have experienced a single demyelinating event will be reviewed by external medical experts when the following information is provided: • Date and details of the most recent neurological examination which must have been conducted within the last ninety days of the request; • The patient’s EDSS is less than or equal to 6.0 (please provide EDSS score); AND • The patient’s clinically isolated syndrome occurred within the last twelve months. Duration of Approval: 1 year Renewal requests will be assessed according to the following criteria: • the requesting physician provides the date and details of the patient’s most recent neurological examination and EDSS scores; • the patient’s neurological examination occurred within that last ninety days; • the patient is stable (i.e. no relapses or attacks during the last year) and • the patient’s EDSS is less than or equal to 6.0 242 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 242, record 143, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Glatiramer Acetate Injection · DIN 02541440 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2024-05-31 Health Canada: Marketed since 2024-04-11 · brand GLATIRAMER ACETATE INJECTION · ATC L03AX13 GLATIRAMER ACETATE · form Solution · route Subcutaneous · ingredients GLATIRAMER ACETATE 20 MG/ML · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Glatiramer Acetate Injection: Formulary list price $27.86 per unit (the source does not state the unit; exact figure $27.8587). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02541440)

Source record
DIN 02541440: Glatiramer Acetate Injection Raw flags: sec12=Y, sec3=Y Item: 920000422; group id 918; item number 2192; lccId 00309; manufacturer id MYL Source form: Inj Sol Pref Syr-1mL Pk; strength: 20mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $27.8587; ministry $27.8587 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02541440 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103009
Interchangeable products
Copaxone · DIN 02245619 · $27.8587
Shortage status: resolved shortage (ended January 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541440
Shortage record checked October 6, 2026

Glatect · DIN 02460661 · 20 mg/mL · injection, pre-filled syringe 1mL Pk

Limited Use, Reason for Use code 535, 536, 537 requiredMarketed · checked October 5, 2026
Write on scriptone applicable Reason for Use code, 535 or 536 or 537 (criteria below)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Ontario Limited Use criteria, code 535, 536, 537
Reason for Use code 535 As monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) meeting ALL the following criteria: -Recent neurological examination consistent with the diagnosis of RRMS; AND -Lesions typical of multiple sclerosis on brain magnetic resonance imaging (MRI); AND -Experienced at least 2 clinical attacks in their lifetime with one attack occurring within the prior year; AND -EDSS score less than or equal to 6.0 prior to start of treatment; AND -Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis. Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 536 As monotherapy for the treatment of patients who have experienced a single demyelinating event/ Clinically Isolated Syndrome (CIS) meeting ALL the following criteria: - CIS occurred within the prior 12 months; AND - Recent neurological examination; AND - Lesions typical of CIS confirmed on brain magnetic resonance imaging (MRI); AND - EDSS score less than or equal to 6.0 prior to start of treatment; AND - Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 537 Renewal of therapy for patients diagnosed with relapsing remitting multiple sclerosis (RRMS) or a single demyelinating event /Clinically Isolated Syndrome (CIS) who meet ALL the following criteria: - Used as monotherapy for the treatment of RRMS or CIS; AND - EDSS score less than or equal to 6.0; AND - Disease activity is stabilized as determined by a neurological exam and the number of clinical relapses experienced while on treatment; AND - Prescribed by a neurologist experienced in the treatment of Multiple Sclerosis (MS) OR a prescriber in consultation with a neurologist overseeing the patient's MS. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Glatiramer acetate – See Formulary listing for Glatect Brand(s): Copaxone, Glatect (available as Limited Use drug on ODB formulary) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection Refer to the Executive Officer Communications on the Ministry website for the Ministry’s Biosimilar Policy including frequently asked questions and updates for the biosimilar policy updates. http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx Effective March 31, 2023, the ODB program will start transitioning coverage for Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan® to their biosimilar versions. Effective December 29, 2023, coverage for these originator biologic drugs through the ODB program will not be available for patients and the ODB program will only provide coverage for the biosimilar version of these drugs for all ODB program recipients, with limited exemptions. In general, for ODB program recipients who are already on these biologic drugs, there is up to a 9-month transition period (see the biosimilar switch policy described on page 6 to 8 of this document). It should be noted that after the date when a biosimilar becomes publicly funded for an approved indication, patients initiated on an originator biologic for this same provincially funded indication through support from a manufacturer’s patient support program, will be expected to be provided ongoing access of the originator biologic through the patient’s original payer mechanism (e.g. manufacturer’s patient support program) or to switch to an ODB funded biosimilar version upon meeting specified criteria. The Ministry will no longer consider funding of originator biologics that are part of the biosimilar policy with limited exemptions on or after December 29, 2023. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 226, record 133, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Glatiramer acetate (Coverage is provided for Glatect) Brand(s): Glatect; Copaxone will only be funded for patients who meet a medical exemption as of December 29, 2023 (Refer to the Biosimilar policy) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection Interferon beta-1a Brand(s): Avonex PS, Avonex Pen DOSAGE FORM/ STRENGTH: 30 mcg/0.5mL prefilled syringe for intramuscular injection, 30 mcg single-use prefilled autoinjector Brand(s): Rebif DOSAGE FORM/ STRENGTH: 22 mcg and 44 mcg prefilled syringe for subcutaneous injection, 66 mcg/ml and 132 mcg/ml pre-filled cartridge Interferon beta-1b Brand(s): Betaseron DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection Brand(s): Extavia DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection For the treatment of Clinically Isolated Syndrome (CIS): requests for patients who have experienced a single demyelinating event will be reviewed by external medical experts when the following information is provided: • Date and details of the most recent neurological examination which must have been conducted within the last ninety days of the request; • The patient’s EDSS is less than or equal to 6.0 (please provide EDSS score); AND • The patient’s clinically isolated syndrome occurred within the last twelve months. Duration of Approval: 1 year Renewal requests will be assessed according to the following criteria: • the requesting physician provides the date and details of the patient’s most recent neurological examination and EDSS scores; • the patient’s neurological examination occurred within that last ninety days; • the patient is stable (i.e. no relapses or attacks during the last year) and • the patient’s EDSS is less than or equal to 6.0 242 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 242, record 143, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
No interchangeable product listed in the Ontario extract
Glatect · DIN 02460661 Manufacturer: Pharmascience Inc.; listing date 2018-09-27 Health Canada: Marketed since 2017-08-21 · brand GLATECT · ATC L03AX13 GLATIRAMER ACETATE · form Solution · route Subcutaneous · ingredients GLATIRAMER ACETATE 20 MG/ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Glatect: Formulary list price $35.84 per unit (the source does not state the unit; exact figure $35.8400). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02460661)

Source record
DIN 02460661: Glatect Raw flags: sec12=Y, sec3=Y Item: 922000001; group id 997; item number 2336; lccId 00309; manufacturer id PMS Source form: Inj Sol-Pref Syr 1mL Pk; strength: 20mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $35.8400; ministry $35.8400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02460661 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94809
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02460661
Shortage record checked October 6, 2026
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 77 more
Full class listing Related classes:

Other drugs in the same formulary class (92:20 Biologic Response Modifiers) and how they are covered

Matched class: 92:20 Biologic Response Modifiers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:20 Biologic Response Modifiers

USTEKINUMAB

· 6 products · Limited Use, codes 668, 669, 671, 672 (4), Limited Use, codes 671, 672 (2) · strengths: 45mg/0.5mL, 90mg/1.0mL, 5mg/mL · Inj Sol-0.5mL Pref Syr Pk (Preservative-Free), Inj Sol-0.5mL Vial Pk (Preservative-Free), Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-26mL Vial Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:20
Full class listing Related classes: 92:36 Disease-Modifying Antirheumatic Agents, 92:44 Immunosuppressive Agents, 92:92 Other Miscellaneous Therapeutic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS COPAXONE (glatiramer acetate) is indicated for: 20 mg/mL once-daily: Treatment of ambulatory patients with Relapsing Remitting Multiple Sclerosis (RRMS), including patients who have experienced a single demyelinating event and have lesions typical of multiple sclerosis on brain MRI: • To decrease the frequency of clinical exacerbations • To reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans. 40 mg/mL three times-a-week: Treatment of ambulatory patients with Relapsing Remitting Multiple Sclerosis (RRMS): • To decrease the frequency of clinical exacerbations • To reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans. The safety and efficacy of COPAXONE in chronic progressive MS have not been established. 1.1 Pediatrics Pediatrics (under 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (over 65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00080212.PDF PM date: APR 11, 2025 Source product: COPAXONE; DIN 02245619; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 28, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated October 05, 2026

Glatiramer acetate – See Formulary listing for Glatect (Copaxone, Glatect (available as Limited Use drug on ODB formulary))

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: See the ministry wording below; no separate indication heading is held.

Ministry criteria corpus 2025-01-01; page 226

Glatiramer acetate – See Formulary listing for Glatect Brand(s): Copaxone, Glatect (available as Limited Use drug on ODB formulary) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection
Refer to the Executive Officer Communications on the Ministry website for the Ministry’s Biosimilar Policy including frequently asked questions and updates for the biosimilar policy updates. http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/eo_communiq.aspx
Effective March 31, 2023, the ODB program will start transitioning coverage for Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan® to their biosimilar versions.
Effective December 29, 2023, coverage for these originator biologic drugs through the ODB program will not be available for patients and the ODB program will only provide coverage for the biosimilar version of these drugs for all ODB program recipients, with limited exemptions. In general, for ODB program recipients who are already on these biologic drugs, there is up to a 9-month transition period (see the biosimilar switch policy described on page 6 to 8 of this document).
It should be noted that after the date when a biosimilar becomes publicly funded for an approved indication, patients initiated on an originator biologic for this same provincially funded indication through support from a manufacturer’s patient support program, will be expected to be provided ongoing access of the originator biologic through the patient’s original payer mechanism (e.g. manufacturer’s patient support program) or to switch to an ODB funded biosimilar version upon meeting specified criteria. The Ministry will no longer consider funding of originator biologics that are part of the biosimilar policy with limited exemptions on or after December 29, 2023.

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Glatiramer acetate (Coverage is provided for Glatect) (Glatect; Copaxone will only be funded for patients who meet a medical)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of Clinically Isolated Syndrome (CIS): requests for patients who have experienced a single demyelinating event will be reviewed by external medical experts when the following information is provided:

Ministry criteria corpus 2025-01-01; page 242

Glatiramer acetate (Coverage is provided for Glatect) Brand(s): Glatect; Copaxone will only be funded for patients who meet a medical exemption as of December 29, 2023 (Refer to the Biosimilar policy) DOSAGE FORM/ STRENGTH: 20 mg/mL pre-filled syringe for subcutaneous injection
Interferon beta-1a Brand(s): Avonex PS, Avonex Pen DOSAGE FORM/ STRENGTH: 30 mcg/0.5mL prefilled syringe for intramuscular injection, 30 mcg single-use prefilled autoinjector
Brand(s): Rebif DOSAGE FORM/ STRENGTH: 22 mcg and 44 mcg prefilled syringe for subcutaneous injection, 66 mcg/ml and 132 mcg/ml pre-filled cartridge
Interferon beta-1b Brand(s): Betaseron DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection
Brand(s): Extavia DOSAGE FORM/ STRENGTH: 0.3 mg/vial subcutaneous injection
For the treatment of Clinically Isolated Syndrome (CIS): requests for patients who have experienced a single demyelinating event will be reviewed by external medical experts when the following information is provided:
• Date and details of the most recent neurological examination which must have been conducted within the last ninety days of the request;
• The patient’s EDSS is less than or equal to 6.0 (please provide EDSS score); AND
• The patient’s clinically isolated syndrome occurred within the last twelve months.
Duration of Approval: 1 year
Renewal requests will be assessed according to the following criteria:
• the requesting physician provides the date and details of the patient’s most recent neurological examination and EDSS scores;
• the patient’s neurological examination occurred within that last ninety days;
• the patient is stable (i.e. no relapses or attacks during the last year) and
• the patient’s EDSS is less than or equal to 6.0
242

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.